Neoleukin Therapeutics, Inc. (NLTX) Q2 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Neurogene Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:04.710 Good afternoon, and thank you for joining us today for the Neoleukin Therapeutics conference 00:00:04.710 -- 00:00:08.931 call. At this time, all participants are in a listen-only mode. 00:00:08.931 -- 00:00:12.893 Following the conclusion of the prepared remarks, we will conduct a question and answer 00:00:12.893 -- 00:00:15.233 session, and instructions will follow at that time. 00:00:15.233 -- 00:00:18.734 As a reminder, today's conference is being recorded. 00:00:18.734 -- 00:00:23.535 I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin 00:00:23.535 -- 00:00:26.863 Therapeutics. Julie, please go ahead. 00:00:26.863 -- 00:00:30.746 Thank you. Good afternoon and welcome to Neoleucin Therapeutics' second quarter 2020-20 00:00:30.746 -- 00:00:32.746 conference 00:00:32.967 -- 00:00:38.130 call. Joining me on the call today from Neoleucin are Jonathan Drachman, CEO, Priti 00:00:38.130 -- 00:00:42.693 Patel, Chief Medical Officer, and Sean Smith, Vice President, Finance. 00:00:42.693 -- 00:00:46.976 Today's call is being recorded. It will be available for replay on the investor relations 00:00:46.976 -- 00:00:51.068 section of the Neoleucin website approximately two hours after the call for at least 00:00:51.068 -- 00:00:56.126 30 days. Before we start, I'd like to remind you that today's call will include forward-looking 00:00:56.126 -- 00:01:01.450 statements based on current expectations. Such statements represent management's judgments, 00:01:01.450 -- 00:01:06.754 intentions, beliefs, and expectations about future events, strategies, product candidates, 00:01:06.754 -- 00:01:08.755 and operating plans. 00:01:08.755 -- 00:01:13.259 All forward-looking statements included in this presentation are ...